Evaluation of the hypothalamo-pituitary-adrenal axis using the cortisol awakening response test in patients with type 1 diabetes mellitus with and without depression: Multicenter Argentine Study (EMA-1)

Authors

  • Adriana Álvarez Italian Hospital of Buenos Aires, Autonomous City of Buenos Aires, Argentina
  • Andrea Kozak Italian Hospital of Buenos Aires, Autonomous City of Buenos Aires, Argentina
  • Lucas Costa National University of the Litoral, Santa Fe, Argentina
  • Guillermo Alzueta Argentine Diabetes Society, Autonomous City of Buenos Aires, Argentina
  • Juan Bauchi Naval Hospital Puerto Belgrano, Bahía Blanca, Province of Buenos Aires, Argentina
  • Claudia De Boni Private Clinic, Mar del Plata, Province of Buenos Aires, Argentina
  • Guillermo Dieuzeide Nuestra Sra. Del Carmen Hospital, Chacabuco, Province of Buenos Aires, Argentina
  • Olga Escobar Diagnos Private Center, Tucumán, Argentina
  • Teresita García Private Clinic, National University of Tucumán, Tucumán, Argentina
  • Patricia Mascaró Private Clinic, Comodoro Rivadavia, Chubut, Argentina
  • Olguita Vera Private Clinic, Río Gallegos, Santa Cruz, Argentina
  • Diego González University of Buenos Aires, Autonomous City of Buenos Aires, Argentina
  • Bibiana Fabre University of Buenos Aires, Autonomous City of Buenos Aires, Argentina
  • Luis Grosembacher Italian Hospital of Buenos Aires, Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/diab.v54i3.454

Keywords:

type 1 diabetes mellitus, hypothalamus-pituitary-adrenal-axis, depression, glycemic control

Abstract

Introduction: depression (DP) has a high prevalence in patients with type 1 diabetes mellitus (DM1) and is associated with negative clinicals consequences like more cardiovascular morbimortality and chronic complications. There are few studies published about the dysregulation of hypothalamo-pituitary-adrenal axis (H-P-A) in DM1 with DP and the relation between DP and the Cortisol Awakening Response Test (CAR) with the glycemic control (GC).

Objectives: examine the functionality of the H-P-A axis using the Cortisol Awakening Response Test (CAR), in patients with DM1 (PD1) with and without DP. Determine the prevalence of DP in PD1 and examine if there is any relation between CAR and GC and DP and poorer GC.

Materials and methods: observational, prospective, national, multicenter study. Patients with DM1, older than 18 years old; Patient Health-9 questionnaire (PHQ-9) was used to diagnose DP and 2 samples of salivary cortisol, and blood samples for glycemia, glycated albumin and Hba1c.

Author Biographies

Adriana Álvarez, Italian Hospital of Buenos Aires, Autonomous City of Buenos Aires, Argentina

Staff Physician of the Endocrinology, Metabolism and Nuclear Medicine Service

Andrea Kozak, Italian Hospital of Buenos Aires, Autonomous City of Buenos Aires, Argentina

Biochemist; Technical Director of the Laboratory of Hormonal and Genetic Endocrinology of the Service of Endocrinology, Metabolism and Nuclear Medicine

Lucas Costa, National University of the Litoral, Santa Fe, Argentina

Bioengineer, Biostatistics Unit, Faculty of Medical Sciences

Guillermo Alzueta, Argentine Diabetes Society, Autonomous City of Buenos Aires, Argentina

Specialist in Endocrinology

Juan Bauchi, Naval Hospital Puerto Belgrano, Bahía Blanca, Province of Buenos Aires, Argentina

Medical specialist; consultant in Endocrinology, senior in Medical Clinic and Diabetes; Master in Psycho-Immuno-Neuro-Endocrinology; Private practice

Claudia De Boni, Private Clinic, Mar del Plata, Province of Buenos Aires, Argentina

Member of the Committee of Psychosocial Aspects of the Argentine Diabetes Society

Guillermo Dieuzeide, Nuestra Sra. Del Carmen Hospital, Chacabuco, Province of Buenos Aires, Argentina

Member of the Psychosocial Aspects Committee of the Argentine Diabetes Society; Chief Internal Medicine Division; Head of the Endocrinology and Diabetes Service

Olga Escobar, Diagnos Private Center, Tucumán, Argentina

Member of the Committee of Psychosocial Aspects of the Argentine Diabetes Society

Teresita García, Private Clinic, National University of Tucumán, Tucumán, Argentina

Member of the Committee of Psychosocial Aspects of the Argentine Diabetes Society

Patricia Mascaró, Private Clinic, Comodoro Rivadavia, Chubut, Argentina

Member of the Committee of Psychosocial Aspects of the Argentine Diabetes Society

Olguita Vera, Private Clinic, Río Gallegos, Santa Cruz, Argentina

Endocrinologist

Diego González, University of Buenos Aires, Autonomous City of Buenos Aires, Argentina

Biochemist, Endocrinology Laboratory, Department of Clinical Biochemistry, Faculty of Pharmacy and Biochemistry

Bibiana Fabre, University of Buenos Aires, Autonomous City of Buenos Aires, Argentina

Biochemist, Endocrinology Laboratory, Department of Clinical Biochemistry, Faculty of Pharmacy and Biochemistry

Luis Grosembacher, Italian Hospital of Buenos Aires, Autonomous City of Buenos Aires, Argentina

Staff Physician, Endocrinology, Metabolism and Nuclear Medicine Service; Head of the Diabetes Section

References

I. International Diabetes Federation (2019) IDF Diabetes Atlas, 9 th edn. International Diabetes Federation, Brussels, Belgium.

II. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care jan 2018; 41 (Suplement 1): S13-S27. doi.org/10.2337/dc18-S002.

III. Rotella F, Mannucci E. Depression as a risk factor for diabetes: meta-analysis of longitudinal studies. J Clin Psychiatry 2013: 74:31-37.

IV. Marcus M, Yasamy TM, van Ommeren M. Chisholm D, Saxena S. World Health Organization WHO Department of Mental Health and Substance Abuse. Disponible en: http://www.who.int/mental/ HYPERLINK "http://www.who.int/mental/health/management/depression/who_paper_depression_wfmh_2012.pdf?ua=1"health/management/depression/who_paper_depression_wfmh_2012.pdf?ua=1

V. International Diabetes Federation. IDF Diabetes Atlas, 6th edn. Brussels, Belgium: International Diabetes Federation, 2013. Disponible en: http://www.idf.org/diabetesatlas.

VI. Anderson RJ, Freedland KE, Clouse RE, Lutsman PJ. The prevalence of comorbid depression in adults with diabetes. Diabetes Care 2001; 24:1069-78.

VII. Lloyd CE, Roy T, Nouwen A, Chauhan AM. Epidemiology of depression in diabetes: international and cross-cultural issues. J Affect Disord 2012; 142 Suppl: S22-29.

VIII. Lloyd CE, Nouwen A, Sartorius N, Ahmed HU, Álvarez A, et al. Prevalence and correlates of depressive disorders in people with type 2 diabetes: results from International Prevalence and Treatment and Diabetes and Depression (INTERPRET-DD) study, a collaborative study carried out in 14 countries. Diabetic Med 2018. DOI: 10.1111/dme.13611.

IX. Grey M, Whittemore R, Tamborlane W. depression in type 1 diabetes in children: natural history and correlates. J Psychosom Res 2002; 53:907-11.

X. Korczak DJ, Pereira S, Koulajian K, Matejcek A, Giacca A. Type 1 diabetes mellitus and major depressive disorder: evidence for biologycal link. Diabetologia 2011; 54:2483-93.

XI. Barnard KD, Skinner TC, Peveler R. The prevalence of co-morbid depression in adults with type 1 diabetes: systematic literature review. Diabet Med 2006; 23:445-448.

XII. Simon G, Katon W, Lin E, et al. Diabetes complications and depression as predictors of health services costs. Gen Hosp Psychiatry 2005; 27:344-51.

XIII. González JS, Esbitt SA. Depression and treatment nonadherence in type 2 diabetes: assesments issues and an integrative treatment approach. Epidemiol Psichiatr Soc 2010 Apr-Jun; 19(2):110-5. Review.

XIV. Lutsman PJ, Andreson RJ, Freedland KE, de Groot M, Carney RM, Clouse RE. Depression and poor glycemic control: a meta-analytic review of the literature. Diabetes Care 2000 Jul; 23(7):934-42.

XV. Badescu SV, Tataru C, Kobylinska L, Georgescu EL, Zahiu DM, Zagrean AM, Zagrean L. The association between diabetes mellitus and depression. J Med Life 2016 Apr-Jun; 9(2): 120-125.

XVI. Herder C, Schmitt A, Budden F, Reimer A, Kulzer B, Roden M, Haak T, Hermanns N. Association between pro- and anti-inflammatory cytokines and depressive symptoms in patients with diabetes-potential differences by diabetes type and depression scores. Translational Psychiatry 2017; 7:1. DOI 10.1038/s41398-017-0009-2.

XVII. Chiodini I, Adda G, Scillitani A, et al. Cortisol secretion in patients with type 2 diabetes: relationship with chronic complications. Diabetes Care 2007; 30:83-8.

XVIII. Carvalho LA, Urbanova L, Hamer M, Hackett RA, Lazzarino AI, Steptoe A. Blunted glucocorticoid andmineralocorticoid sensitivity to stress in people with diabetes. Psychoneuroendocrinology 2015; 51:209-18. DOI: 10.1016/j.psyneuen. 2014 09.023. Epub 2014 Sep 30.

XIX. Melin EO, Thunander M, Landin-Olsson M, Hillman M, Thulesius HO. Depression, smoking, physical inactivity and season independently associated with midnight salivary cortisol in type 1 diabetes. BMC Endocrine Disorders 2014; 14:75. Disponible en: http//www.biomedcentral.com/1472-6823/14/75.

XX. Wilhelm I, Born J, Kudielka BM, Schlotz W, Wust S. Is the cortisol awakening rise a response to awakening? Pshychoneuroendocrinology 2007; 32:358.366.

XXI. Lederbogen F, Hummel J, Fademrecht C, et al. Flattened circadian cortisol rhythm in type 2 diabetes. Exp Clin Endocrinol Amp Diabetes 2011; 119(9):573-575. DOI:0.055/s-0031-1275288.

XXII. Hackett RA, Steptoe A, Kumari M. Association of diurnal patterns in salivary cortisol with type 2 diabetes in the Whitehall II study. J Clin Endocrinol Metab 2014 Dec; 99(12): 4625-4631.Doi: 10.1210/jc.2014-2459.

XXIII. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Med 2001 Sep; 16(9):606-13.

XXIV. Janssen EP, Kohler S, Stethouwer CD, Schaper NC, et al. The patient health Questionnaire-9 as a screening tool for depression in individuals with type 2 diabetes mellitus: The Maastricht Study. J Am Geriatr Soc 2016 Nov; 64(11):e201-e6. PubMed PMID: 27783384.

XXV. Lloyd CE, Nouwen A, Sartorius N, Ahmed HU, Álvarez A, et al. Research: Educational and psychological aspects. Prevalence and correlates of depressive disorders in people with type 2 diabetes: results from the International Prevalence and Treatment of Diabetes and depression (INTERPRET-DD) study, a collaborative study carried out in 14 countries. Diabetic Medicine 2018 Jun; 35(6):760-769 DOI: 10.1111/dme 13611.

XXVI. Petrak F, Baumeister HM, Skinner TC, Brown A, Holt RIG. Depression and diabetes: treatment and health-care delivery. Lancet Diabetes Endocrinol 2015; 3:472-485.

XXVII. Diez-Quevedo C, Rangil T, Sánchez-Planell L, Kroenke K, et al. Validation and utility of the patient helath questionnaire in diagnosing mental disorders in 1003 General Hospital Spanish Inpatients. Psychosom Med 2001; 63: 679-86.

XXVIII. Van Dooren FEP, Nefs G, Schram MT, Verhey FRJ, Denollet J, Pouwer F. Depression and risk of mortality in people with diabetes mellitus: a systematic review and meta-analysis. PloS ONE 2013; 8(3): e57058. DOI:10.1371/journal.pone.0057058.

XXIX. Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affect Disord 2012; 142(S1):S8-S21.

XXX. Ismail K, Sartorius N: Unraveling the pathogenesis of depression diabetes link. In: Depression and diabetes. Edited by Katon W, Maj M. Oxford,UK: Wiley-Blackwell; 2010; 29-62.

XXXI. Clow A, Hucklebridge F, Stalder T, Evans P, Thorn P. The cortisol awakening response: more than a measure of HPA axis function. Neuroscience & Biobehavioral Reviews 2010; 35 (1):97-103.

XXXII. Clow A, Hucklebridge F, Thorn L. The cortisol awakening response in context. Int Rev Neurobiol 2010; 93:153-75.

XXXIII. Vrshek-Schallhorn S, Doane LD, Mineka S, Zinbarg RE, Craske MG, Adam EK. The cortisol awakening response predicts major depression: predictive stability over a 4-year follow-up and effect of depression history. Psychol Med 2013; 4434(3):483-93.

XXXIV. Stroud CB, Vrshek-Shallhorn S, Norkett EM, Doane LD. The cortisol awakening response (CAR) interacts with acute interpersonal stress to prospectively predict depressive symptons among early adolescent girls. Psychoneuroendocrinology 2019; 9-18.

XXXV. Adam EK, Doane LD, Zinbarg RE, Mineka S, et al. Prospective prediction of major depressive disorder from cortisol awakening responses in adolescence. Psychoneuroendocrinology 2010 Jul; 35(6):921-31.

XXXVI. Vreeburg SA, Hoogendijk WJ, van Pelt J, et al. Major depressive disorder and hypothalamic-pituitary-adrenal axis activity: results from a large cohort study. Arch Gen Psychiatry 2009; 66(6):617-626.

XXXVII. American Diabetes Association Glycemic Targets: Standars of Medical Care in Diabetes-2020. Diabetes Care 2020 Jan; 43 (Supplement 1): S66-S76.

XXXVIII. Kumari M, Shipley M, Stafford M, Kivimaki M. Association of diurnal patterns in salivary cortisol with all-cause and cardiovascular mortality: findings from Whitehall II study. J Clin Endocrinol Metab 2011;96:1478-1485.

XXXIX. Stagnaro JC, Cía A, Vázquez N, Vommaro H, et al. Estudio epidemiológico de salud mental en población general de la República Argentina. VERTEX Revista Arg De Psiquiat 2018; Vol.XXIX:275-299.

XL. Strandberg RB, Graue M, Wentzel-Larsen T, Peyrot M, Rokne B. Relationships of diabetes-specific emotional distress, depression, anxiety, and overall well-being with HbA1c in adults persons with type 1 diabetes. J Psychosom Res 2014 Sep;77(3):174-9.

Downloads

Published

2023-01-10

How to Cite

Álvarez, A., Kozak, A., Costa, L., Alzueta, G., Bauchi, J., De Boni, C., Dieuzeide, G., Escobar, O., García, T., Mascaró, P., Vera, O., González, D., Fabre, B., & Grosembacher, L. (2023). Evaluation of the hypothalamo-pituitary-adrenal axis using the cortisol awakening response test in patients with type 1 diabetes mellitus with and without depression: Multicenter Argentine Study (EMA-1). Journal of the Argentine Society of Diabetes, 54(3), 132–139. https://doi.org/10.47196/diab.v54i3.454

Issue

Vol. 54 No. 3 (2020): September/December 2020

Section

Original article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.

La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.

Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.

 

Most read articles by the same author(s)

1 2 3 4 > >>